TIRZEPATIDE (MOUNJARO®) AND THE ROLE OF THE CLINICAL PHARMACIST: INNOVATION AND CHALLENGES IN THE TREATMENT OF OBESITY

Abstract

Obesity is a chronic and multifactorial disease associated with several metabolic and cardiovascular comorbidities. Lifestyle changes are essential but often insufficient to ensure sustained weight loss, making pharmacological therapy necessary. Tirzepatide, a dual GIP and GLP-1 receptor agonist, provides significant benefits in weight reduction, glycemic control, and metabolic improvement. Clinical trials such as SURPASS-1 and SURPASS-2 have demonstrated superior efficacy compared to semaglutide and placebo, with mild adverse effects. This study aims to highlight the advantages of Tirzepatide for weight loss, emphasizing the pharmacist’s role in patient education, adherence, and treatment safety. It is a narrative literature review based on articles published between 2015 and 2025 in the PubMed and SciELO databases. Tirzepatide represents a major advancement in obesity management and reinforces the importance of integrated pharmaceutical care to ensure rational and safe use. However, further long-term studies are needed to assess its safety and effects in prolonged use.